/ /

  • linkedin
  • Increase Font
  • Sharebar

    Weighing pros, cons of IOL implantation in pediatric cataract

    Study with children under age of 2 finds equal rate of glaucoma but more posterior synechiae


    Taking a closer look

    In his research, Dr. Vasavada wanted to take a closer look at outcomes and safety for the treatment of bilateral cataract in patients under the age of 2. The prospective, randomized, study analyzed results for up to 5 years and looked at complications.

    The study included 60 eyes with hydrophobic single-piece IOL implantation and 60 eyes with aphakia. Dr. Vasavada performed all surgeries.

    To help motivate parents and their children return for numerous follow-up exams, the office helped support their travel.

    The study examined glaucoma (defined as an IOP of more than 21 mm Hg), visual obscuration, and inflammation (e.g., synechiae and cell deposits).

    Related: Glaucoma gene therapy on positive trajectory using CRISPR-Cas9

    The rate of glaucoma in the aphakic group was 16.7% and 13.4% in the pseudophakic group. Visual axis obscuration was 6.3% in the aphakic group and 10% in the pseudophakic group. Posterior synechiae occurred in 10% of aphakic patients and 25% of pseudophakic patients. There were also some cell deposits in the pseudophakic group, but they disappeared after 6 months postoperatively.

    The glaucoma rate between the two groups was essentially the same, Dr. Vasavada said. However, the difference in the rate of posterior synechiae was significant.

    More glaucoma: Rocket 2 meets safety endpoints for netarsudil

    Abhay Vasavada, MS, FRCS

    E: [email protected]

    This article was adapted from Dr. Vasavada’s presentation at the 2015 meeting of the American Academy of Ophthalmology. He did not indicate any proprietary interest in the subject matter.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results